Source published Aug 23, 2026, 09:29 PM UTC · Operation recorded Aug 27, 2026, 08:22 AM UTC

Moderna's Phase 3 trial for its personalized cancer vaccine in combination with Keytruda met its primary endpoint of improving recurrence-free survival, and the stock surged 177% on the news. This is a material positive catalyst for the company.

Source published Aug 23, 2026, 09:29 PM UTC · Operation recorded Aug 27, 2026, 08:17 AM UTC

Moderna's Phase 3 cancer vaccine trial succeeded, with patients receiving the custom shot plus Keytruda going longer without cancer recurrence, and shares closed 177% higher. This is a material positive catalyst for Moderna.

Source published Aug 23, 2026, 09:29 PM UTC · Operation recorded Aug 27, 2026, 08:12 AM UTC

Moderna's Phase 3 cancer vaccine trial succeeded, with patients receiving the treatment plus Keytruda going longer without cancer recurrence. This is a material positive catalyst for Moderna.

Source published Aug 23, 2026, 09:29 PM UTC · Operation recorded Aug 27, 2026, 08:07 AM UTC

Moderna's Phase 3 cancer vaccine trial succeeded, showing improved recurrence-free survival when combined with Keytruda. This is a material positive catalyst for Moderna, and the stock surged 177% on the news.

Source published Aug 23, 2026, 09:29 PM UTC · Operation recorded Aug 27, 2026, 08:02 AM UTC

Moderna reported positive Phase 3 results for its personalized cancer vaccine, causing a 177% one-day share increase. This is a material positive catalyst for the company.

Source published Aug 23, 2026, 09:29 PM UTC · Operation recorded Aug 27, 2026, 07:57 AM UTC

Moderna reported positive Phase 3 results for its personalized cancer vaccine, a significant positive catalyst that led to a 177% stock surge. This supports a BUY operation.

Source published Aug 23, 2026, 09:29 PM UTC · Operation recorded Aug 27, 2026, 07:52 AM UTC

Moderna and Merck reported positive Phase 3 results for their personalized cancer treatment, showing longer recurrence-free survival compared to Keytruda alone. Moderna shares surged 177% on the news, indicating a strong positive market reaction and improved expected fundamentals.

Source published Aug 23, 2026, 09:29 PM UTC · Operation recorded Aug 27, 2026, 07:47 AM UTC

Moderna and Merck reported positive Phase 3 results for their personalized cancer treatment, showing improved recurrence-free survival compared to Keytruda alone. This is a material positive catalyst for Moderna.

Source published Aug 23, 2026, 09:29 PM UTC · Operation recorded Aug 27, 2026, 07:42 AM UTC

Moderna reported positive Phase 3 results for its personalized cancer vaccine, a material positive catalyst that drove a 177% stock surge. This supports a BUY operation.

Source published Aug 23, 2026, 09:29 PM UTC · Operation recorded Aug 27, 2026, 07:37 AM UTC

Segments 13-16 report that Moderna's personalized cancer treatment succeeded in a Phase 3 trial, leading to a 177% share price increase. This is a material positive catalyst for Moderna.